Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc (NASDAQ: POAI) delivers AI-powered solutions for personalized cancer treatment through its integrated biobank data and machine learning platforms. This news hub provides investors and researchers with essential updates about the company's advancements in precision oncology.
Access real-time information on POAI's FDA-cleared medical systems, clinical trial partnerships, and AI-driven drug discovery milestones. Our curated collection includes earnings reports, technology validations, and strategic collaborations that demonstrate the company's progress in transforming cancer care.
Key updates cover three operational segments: AI-driven tumor modeling from Pittsburgh labs, biopharma contract research developments in Birmingham, and STREAMWAY System adoption in clinical settings. Stay informed about biomarker discovery breakthroughs and peer-reviewed study publications.
Bookmark this page for streamlined access to POAI's verified financial disclosures, scientific presentations, and regulatory filings. Check regularly for updates on how the company's 150,000+ tumor sample database informs next-generation oncology solutions.
Predictive Oncology Inc. (NASDAQ: POAI) will report its financial results for the first quarter ended March 31, 2024 on Wednesday, May 15, 2024. The company, known for leveraging AI and machine learning in oncology drug discovery, will host a corporate update conference call and webcast at 8:30 a.m. ET.
Predictive Oncology Inc. announces a collaboration with FluGen to develop a first-of-its-kind intranasal flu vaccine, funded by a $6.2 million Phase 2B grant from the DoD. Predictive Oncology's biologics team will work on creating a stable and soluble formulation for the vaccine, addressing the need for longer shelf-life and global distribution. The project aims to enhance the stability of FluGen's M2SR flu vaccine, enabling advanced clinical trials and promising outcomes.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
